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Objective: The frequent association between the type 2 diabetes mellitus and cardio-vascular
diseases suggests that metabolic factors may contribute to cardio-vascular remodeling. The aim of
our study was to examine the relationships between left ventricular posterior wall thickness
(LVPWT), pulse wave velocity (PWV), and the metabolic abnormalities of insulin resistance
syndrome, in hypertensive patients.
Methods: In 227 consecutive hypertensives, we examined the relationships between LVPWT,
PWV, and metabolic factors: plasma glucose, insulin, total cholesterol, high density lipoprotein
(HDL)-cholesterol, triglycerides levels as well as the homeostasis model assessment of insulin
resistance (HOMA). The Pearson correlation coefficient and multiple regression analysis (including
age, gender, body mass index, and 24-hour systolic blood pressure) were used as statistical tests.
Results: In univariate analysis, glucose, HDL-cholesterol, and triglycerides levels were related
to LVPWT (r = 0.19, p < 0.05; r = –0.26, p < 0.001; r = 0.31, p < 0.001, respectively); all
metabolic variables, except HDL-cholesterol, correlated to PWV (plasma glucose r = 0.25,
p < 0.001; total cholesterol r = 0.22, p < 0.01; triglycerides r = 0.20, p < 0.01; insulin r = 0.19,
p < 0.01; HOMA r = 0.27; p < 0.001). In the multivariate model, plasma triglycerides remained
correlated with LVPWT (β = 0.19, p < 0.02) independently of systolic blood pressure, plasma
aldosterone, and normetanephrine. Only HOMA and insulin level remained associated with
PWV (β = 0.14; β = 0.13 respectively, p < 0.05).
Conclusions: These data suggest that among typical metabolic abnormalities of insulin resistance
syndrome, plasma triglycerides, and insulin as well as degree of insulin resistance may contribute
to cardiac hypertrophy and arterial stiffening independently of hemodynamic and hormonal factors.
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Introduction
Approximately 50% of hypertensive patients have an insulin resistance syndrome
(Ginsberg 2000). It has been shown that insulin resistance is a risk factor for
atherosclerosis and cardiac hypertrophy (Harano et al 1996; Devereux et al 2000).
Indeed, cardiac hypertrophy is associated with insulin resistance syndrome even in the
absence of hypertension (Lauer et al 1991; Grossman et al 1992; Sundstrom et al
2000a). Moreover, type 2 diabetic hypertensives have an increased left ventricular
mass (LVM) when compared to non diabetic subjects, independently of age, sex, body
size, and blood pressure (Palmieri et al 2001).
The results of numerous studies concerning the associations between the degree of
insulin resistance and the LVM are conflicting (Davis et al 2002; Kumaran et al 2002;
Galvan et al 2000; Malmqvist et al 2002). Insulin or insulin sensitivity were not
related to left ventricular hypertrophy in the Losartan Intervention For Endpoint
reduction in hypertension (LIFE) substudy, Insulin CARotids US Scandinavia
(ICARUS) (Olsen et al 2003). In the Framingham Heart Study, a positive relationship
was reported between the degree of insulin resistance (by the homeostasis model
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assessment––HOMA) and cardiac hypertrophy only in
women, but this relation was largely accounted for by obesity
(Rutter et al 2003). In contrast, Paolisso et al (1997) has
demonstrated that in hypertensive patients insulinemia
was significantly related to myocardial wall thickness
but not to LVM. Another important marker of insulin
resistance syndrome, hypertriglyceridemia, was also
proposed as an independent predictor of LVM, but the
available data relating triglyceride levels and LVM are
often indirect and inconsistent (Guida et al 2001;
Sundstrom et al 2000b; Palmieri et al 1999). A Swedish
prospective cohort study demonstrated that, in the general
population, plasma triglycerides at the age of 50
predicted the prevalence of left ventricular hypertrophy
20 years later, independently of obesity and blood
pressure (Sundstrom et al 2000b).
Metabolic factors may also be involved in vascular
remodeling, as suggested by the increased arterial stiffness
and the higher prevalence of atherosclerosis in type 2 diabetes
or in the presence of the metabolic syndrome (Devereux
et al 2000; Ferreira et al 2005). In the Atherosclerosis Risk in
Communities Study (ARIC) study, arterial stiffness estimated
by Young’s elastic modulus was associated with glucose,
insulin, and triglycerides levels, in type 2 diabetic and in
non diabetic subjects as well (Salomaa et al 1995). These
results have not been confirmed by van Dijk et al (2003)
who found only insulin-mediated glucose uptake positively
associated with carotid-femoral pulse wave velocity (PWV)
in diabetics.
Evidence presented in ICARUS, a LIFE substudy, has
demonstrated that the level of insulin and the degree of insulin
resistance were independent predictors of arterial stiffness
only in never treated hypertensives (Olsen et al 2000). In
hypertensive patients the increased stiffness of the carotid
artery was primarily due to the increased level of blood
pressure, and aortic PWV was strongly associated with
cardiovascular risk (Blacher et al 1999; Bussy et al 2000).
Considering left ventricular mass and PWV as
independent cardiovascular risk factors, we previously
pointed to the hemodynamic and neuro-hormonal predictors
of the left ventricular posterior wall thickness (LVPWT) and
PWV in hypertensive patients (Legedz et al 2003).
Hypertension is often associated with insulin resistance, and
here our working hypothesis for the present investigation
was that metabolic variables reflecting insulin resistance are
additional and independent determinants of LVPWT and
PWV in hypertensive subjects.
Methods
Cohort of patients in the study
We studied 227 patients (53.3 ±13.4 years of age; 126 men)
(mean ±SD) consecutively referred to a cardiology department
for a standardized hypertension work-up because of
uncontrolled blood pressure and/or suspicion of secondary
hypertension. The history of elevated blood pressure lasted
10 ±9.8 years (mean ±SD). At least 1 week before the
hospitalization, current anti-hypertensive treatment was
withdrawn and, when deemed mandatory, replaced by a calcium
channel blocker and/or a ±α1-adrenoceptor antagonist.
Measurements
A 24-hour blood pressure recording was performed in all
patients. Measurements were obtained every 15 min during
daytime and every 30 min during night-time (Diasys monitor
200RS: Novacor, Rueil-Malmaison, France or Spacelabs
device 90207, Redmond, Washington, USA). The average
24-hour measurements of systolic blood pressure was used.
M-mode, two-dimensional echocardiography was performed
using a VividFive (GE Medical Systems) device equipped
with a 2.5 MHz mechanical transducer. Two or three
measurements of LVPWT were obtained and averaged for
each patient in the partial left lateral supine position, at end-
diastole by the leading-edge-to-leading-edge technique.
Carotid-femoral PWV, a direct measure of arterial stiffness,
was measured by use of the Complior device (Colson,
Garges-les-Gonesse, France) as previously described (Asmar
et al 1995). An average of 25 measurements have been
reported for each patient.
Blood samples for measurements of metabolic variables
were obtained in the morning after an overnight recumbency,
under fasting conditions. Plasma glucose was analysed by
the glucose oxidase method. Plasma cholesterol and
triglyceride levels were assayed using an enzymatic procedure
(Dade-Behring, Liederbach, Germany). A commercial
radioimmunoassay kit was used for measuring plasma
immunoreactive insulin level (INS-IRMA BioSource,
Camarillo, California, USA). Insulin sensitivity was
calculated according to the homeostasis model assessment
(HOMA), using the formula (fasting glucose in mmol/L ×
fasting insulin in µmol/L)/22.5 (Matthews et al 1985).
Statistical analysis
Values are expressed as means ±SD. Plasma glucose,
triglycerides, insulin, and HOMA were log-transformed priorVascular Health and Risk Management 2006:2(4) 487
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to statistical analysis because of an asymmetrical distribution.
The relationships between LVPWT, PWV, and metabolic
variables (plasma glucose, total cholesterol, high density
lipoprotein (HDL)-cholesterol, triglycerides and insulin
levels, and HOMA) were tested by the Pearson correlation
coefficient, then by multiple linear regression analysis. The
potential confounding factors: age, gender, body mass index
(BMI), and systolic blood pressure (SBP) were included in
multivariate model.
Plasma aldosterone and normetanephrine levels, which
proved to be significantly associated with LVPWT in an
earlier study (Legedz et al 2003), were also included in the
multivariate model. A two-sided p value less than 0.05 was
considered to indicate statistical significance. The statistical
package used was STATISTICA 6.0 (Statsoft Inc, Tulsa).
Results
Clinical and demographic characteristics of the patients are
presented in Table 1. Sixteen percent of patients were treated
for type 2 diabetes and 21% for dyslipidemia. Three percent of
patients had angina pectoris and 1.3% presented with peripheral
arterial disease of the lower limbs. A history of myocardial
infarction was found in 0.9% of subjects and a history of
stroke in 10.6%. Smokers of at least 5 cigarettes a day made
up 17% of the population. On clinical examination, no signs
of significant valvular disease or heart failure were found.
The 24-hour blood pressure reported is a recording of
60–70 measurements for each patient. A qualitatively
satisfactory echocardiographic measurement of LVPWT could
be obtained in 164 subjects.
In univariate analysis LVPWT was significantly correlated
to BMI and SBP (r = 0.20, p < 0.01; r = 0.37, p < 0.001,
respectively).
A significant correlation was found with plasma glucose,
HDL-cholesterol, and triglyceride levels (Table 2). There were
no relationships between insulin, total cholesterol or HOMA,
and LVPWT. In multivariate analysis, among the variables
mentioned above, plasma triglycerides remained
independently correlated with LVPWT (β = 0.22 and β = 0.18;
p < 0.01 when glycemia and insulinemia were included in the
model, and β = 0.19; p < 0.02 when HOMA was included in the
model), even after adjustment for other important factors
determining left ventricular wall thickness such as plasma
aldosterone and normetanephrine (Table 3). The independent
contribution of triglycerides to LVPWT determination was
estimated at 19%.
In univariate analysis, PWV which was dependent on
age, BMI and SBP (r = 0.55, r = 0.23 and r = 0.49, respectively,
with p < 0.001 for all), was positively associated with all
metabolic variables, except plasma HDL-cholesterol level
(Table 2). In multiple regression analysis, only insulin level
(β = 0.14; p < 0.04 when total cholesterol level included in
the model and β = 0.13; p < 0.05 when HDL-cholesterol
include in the model) and HOMA (β = 0.14, p < 0.04 when
total or HDL-cholesterol included in the model) remained
independent correlates of PWV (Table 3).
Table1  Clinical characteristics of patients included in the study
Number of patients Mean ±SD
Age (years) (Men [n, %]) 227 53.3 ± 13.4 (126 [55])
Body mass index (kg/m
2) 227 26.8 ± 4.5
Systolic blood pressure (mmHg) 227 155 ± 18.7
Diastolic blood pressure (mmHg) 227 93 ± 12.6
Heart rate (bpm) 227 73 ± 10.2
LVPWT (mm) 164 10.7 ± 2.5
PWV (m/s) 222 12.5 ± 3.5
Total cholesterolemia (mmol/L) 224 5.33 ± 0.97
HDL-cholesterolemia (mmol/L) 219 1.46 ± 0.46
Triglyceridemia (mmol/L) 223 1.23 ± 0.67
Glycemia (mmol/L) 221 5.25 ± 1.13
Insulinemia (mU/L) 214 10.01 ± 5.02
HOMA 210 2.4 ± 1.5
Anti-hypertensive medication (n, %) 172 (76)
Lipid-lowering medication (n, %) 47 (21)
Anti-diabetic medication (n, %) 36 (16)
Note: The number of subjects available for each measurement is given because, in some cases, measurements could not be obtained.
Abbreviations: LVPWT, left ventricular posterior wall thickness; PWV, carotid-femoral pulse wave velocity; HOMA, homeostasis model assessment.Vascular Health and Risk Management 2006:2(4) 488
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When the sample was restricted to these patients with a
measurable LVPWT, similar trends were observed with regard
to the relationships between PWV and HOMA (r = 0.21,
p < 0.01 in univariate analysis and p = 0.06 in multivariate
model). The correlation between PWV and plasma insulin
level in this cohort (ie, in patients with measurable LVPWT),
was still significant in univariate analysis (r = 0.17, p < 0.05)
but not in multivariate model (p = 0.17).
Discussion
In the present study we showed that plasma triglyceride levels
but not insulin resistance was associated with left ventricular
wall thickness independently of hemodynamic and neuro-
hormonal factors in hypertensive subjects. In contrast,
insulinemia and the degree of insulin resistance were
associated with an impairment of arterial elasticity in addition
to age and SBP.
Evidence from previous studies that were carried out in
different types of populations (general population,
hypertensives, diabetics, subjects at high cardiovascular risk)
are inconsistent. Most of these investigations did not find any
relationship between glycemia, insulinemia or degree of insulin
resistance, and left ventricular mass (Malmqvist et al 2002;
Olsen et al 2003; Rutter et al 2003). In contrast, lipid variables
as total cholesterol, HDL-cholesterol or triglyceride levels
were more frequently associated with cardiac remodeling. In
the study of Schillaci et al (2001) an inverse correlation was
found between HDL-cholesterol and LVM in untreated
hypertensive subjects while triglyceride level showed a
positive association with LVM only in univariate analysis.
An increase in plasma triglyceride level is frequently
associated with concomitant decrease in HDL-cholesterol in
the insulin resistance syndrome, and can represent a marker
of metabolic alterations (Guida et al 2001). In our present
study, even though both HDL-cholesterol and triglycerides
level are related to left ventricular wall thickness in univariate
analysis, only triglycerides are strongly correlated with left
ventricular mass independently of other classical confounders
Table 2  Univariate analysis for the relationships between LVPWT, PWV and metabolic factors
Chol HDL Trigly Gluc Insulin HOMA
LVPWT ns r = –0.26 r = 0.31 r = 0.19 ns ns
p < 0.001 p < 0.001 p < 0.05
PWV r = 0.22 ns r = 0.20 r = 0.25 r = 0.19 r = 0.27
p < 0.01 p < 0.01 p < 0.001 p < 0.01 p < 0.001
Abbreviations: LVPWT, left ventricular posterior wall thickness; PWV, carotid-femoral pulse wave velocity; Gluc, plasma glucose level; Chol, plasma total cholesterol
level; HDL, plasma high density lipoprotein-cholesterol level; Trigly, plasma triglycerides level; HOMA, homeostasis model assessment.
Table 3 Multivariate analysis for the relationships between LVPWT, PWV and metabolic factors
R
2 Age Sex BMI SBP Aldo Nadr Gluc Chol Trigly Insul
LVPWT 0.40 ns ns ns p < 0.01 p < 0.01 p < 0.001 ns ns p < 0.01 ns
β = 0.24 β = 0.23 β = 0.31 β = 0.22
PWV 0.47 p < 0.001 ns ns p < 0.001 ns ns ns ns ns p < 0.04
β = 0.44 β = 0.39 β = 0.14
R2 Age sex BMI SBP Aldo Nadr Gluc HDL Trigly Insul
LVPWT 0.40 ns ns ns p < 0.01 p < 0.01 p < 0.001 ns ns p < 0.01 ns
β = 0.23 β = 0.21 β = 0.33 β = 0.18
PWV 0.44 p < 0.001 ns ns p < 0.001 ns ns ns ns ns p < 0.05
β = 0.44 β = 0.37 β = 0.13
R2 Age sex BMI SBP Aldo Nadr HDL Trigly HOMA
LVPWT 0.40 ns ns ns p < 0.01 p < 0.01 p < 0.001 ns p < 0.02 ns
β = 0.23 β = 0.21 β = 0.32 β = 0.19
PWV 0.44 p < 0.001 ns ns p < 0.001 ns ns ns ns p < 0.04
β = 0.43 β = 0.37 β = 0.14
Abbreviations: LVPWT, left ventricular posterior wall thickness; PWV, carotid-femoral pulse wave velocity; BMI, body mass index; SBP, systolic blood pressure; Aldo, plasma
aldosterone level; Nadr, plasma metanoradrenaline level; Gluc, plasma glucose level; Chol, total plasma cholesterol level; HDL, plasma high density lipoprotein-cholesterol
level; Trigly, plasma triglycerides level; HOMA, homeostasis model assessment, β, regression coefficient β evaluating the relative contribution of each predictive variable.Vascular Health and Risk Management 2006:2(4) 489
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in multivariate analysis. These data are in agreement with
results of the Sundstrom et al (2000b) longitudinal study
spanning 20 years that highlighted the triglyceride level as
predictor of left ventricular hypertrophy. Taken together, there
is a good deal of evidence suggesting that plasma lipids are
a possible link between metabolic alterations and cardiac
hypertrophy. Indeed, it was demonstrated that genetic defects
or pharmacological inhibition of several energy production
pathways cause hypertrophic forms of cardiomyopathy (Kelly
2002). For example, fasting or pharmacological inhibition
of fatty acids oxidation leads to myocardial lipid accumulation
and cardiac hypertrophy in rats and in peroxisome
proliferator-activated receptor α (PPARα)-null mice
(Campbell et al 2002). The PPARα, a major regulator of fatty
acid oxidation, may be a link between myocardial lipid
metabolism and hypertrophy. PPARα activity and gene
expression decrease in the pressure overloaded heart in rodent
models (Sack et al 1996; Barger et al 2000). These
experimental data suggest an association between a reduction
in the PPARα-mediated control of myocardial lipid
metabolism, an intracellular triglyceride accumulation, and
the pathological cardiac hypertrophic response.
A decrease in cardiac PPARα activity is conceivable in
human hypertension favoring intracellular triglyceride
accumulation and hypertrophic response. The metabolic
perturbations of insulin resistance syndrome leading to
hypertriglyceridemia may aggravate this process. This
hypothesis opens the way for a new approach to prevention
or treatment of cardiac hypertrophy, and it can be speculated
that fibrates, PPARα activators, and hypotriglyceridemic
drugs, may be beneficial.
In the present study, we also demonstrated that, unlike
LVPWT, arterial stiffness was associated with all metabolic
factors in univariate analysis. After adjustment for age, sex,
BMI, and SBP, only plasma fasting insulin level and the
degree of insulin resistance were correlated with PWV. Other
factors such as plasma glucose, total cholesterol and
triglycerides levels being strongly related to age and/or BMI
did not appear as significant correlates with PWV in
multivariate analysis. Currently, only age and SPB are
considered as independent determinants of arterial stiffness
(Amar et al 2001; Mackey et al 2002). The present study
pointed to the weak but significantly independent
participation of insulin level and degree of insulin resistance
in arterial stiffness determination. This is in agreement with
data of ICARUS, a LIFE sub-study, undertaken in similar
population of hypertensive subjects (Olsen et al 2000). These
results are consistent with the fact that (1) type 2 diabetes is
an important risk factor for atherosclerotic diseases and (2)
even strict glycemic control in type 2 diabetics does not
improve cardiovascular mortality due to macroangiopathy
(UKPDS Group 1998). In contrast, an improvement in glucose
tolerance with angiotensin-converting enzyme inhibitors or
angiotensin II type 1 receptor antagonists, results in reduction
of cardiovascular risk in hypertensive and/or diabetic subjects
(HOPE Study Investigators 2000) as well as in decrease in
arterial stiffness (LIFE study). These results also suggest that
in our hypertensive, only moderately insulino-resistant
(HOMA = 2.4) patients, the degree of insulin resistance could
influence arterial stiffening. Thus, an improvement of insulin
resistance state and a decrease in plasma insulin level may be
very important for the reduction of arterial stiffening, in addition
to blood pressure control, even in non diabetic hypertensives.
At the cellular and molecular levels, our results are
supported by the fact that insulin has demonstrated
proliferative effects on cultured vascular smooth muscle cells;
it also enhances lipid synthesis and low density lipoprotein
binding to these cells as well as connective tissue synthesis
in arterial wall (Stout 1992; Bouguerra et al 2001).
Accordingly, these data suggest that among typical
metabolic abnormalities of insulin resistance syndrome,
plasma triglycerides and insulin may contribute to the increased
cardiovascular risk, and could represent targets for prevention
and/or treatment of cardiac hypertrophy and arterial stiffening,
in hypertensive subjects. The dissociation between triglyceride
on one hand, and insulin and insulin resistance on the other
hand, as possible determinants of cardiac hypertrophy and
vascular stiffening may also help in individualizing
therapeutic approaches in hypertensive patients.
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